Skip to main content
| News

Roivant invests 200 million dollars in Immunovant

06.08.2021

The Basel-based Roivant Group has invested a total of 200 million dollars in the US biopharmaceutical company Immunovant. This investment is designed to drive forward the development of a drug to treat autoimmune diseases. Immunovant also operates a branch office in Basel.

Roivant Sciences has made a strategic investment in the amount of 200 million US dollars in Immunovant. This fresh capital injection should primarily serve to drive forward the development of the drug candidate IMVT-1401 for the treatment of various autoimmune diseases.

According to a press release, Roivant Sciences has acquired 17,021,276 ordinary shares in Immunovant at a price of 11.75 dollars per share. The investment sees the company’s stake in Immunovant increase from 57.5 percent to 63.8 percent – based on Immunovant’s cash balance and share count as of March 31, 2021.

Over the next 12 months, Immunovant intends not only to continue the existing studies in relation to IMVT-1401, but also to initiate two new clinical trials, according to comments in the press release from Peter Salzmann, CEO of Immunovant.

“We are incredibly excited about the prospects for IMVT-1401, and we are eager to support Immunovant through this investment”, says Matt Gline, CEO of Roivant Sciences, in the press release.

Roivant Sciences focuses on the development of innovative drugs in the areas of neurology, oncology, endocrinology, dermatology and hepatology. The Group’s global headquarters have been located in Basel since 2016.

Immunovant is listed on the NASDAQ-GS stock exchange in the USA and also operates a branch office in Basel.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Advanced Manufacturing/AI, Basel Area Business & Innovation, Innovation, Invest, Sustainability

KUORI developing biodegradable plastics

The Basel-based cleantech company KUORI GmbH develops alternative materials for conventional plastics. The aim is to reduce the accumulation of...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Cell and gene therapies gain momentum in Basel

Companies specializing in the research and development of innovative cell and gene therapies continue to spring up all around the...

Read More
BLKB expanding support for startups
Basel Area Business & Innovation, Innovation, Invest

BLKB expanding support for startups

BLKB offers particularly promising SMEs and startups financial support within the framework of the “100 fürs Baselbiet” program. These companies...

Read More
Combatting the rise of antimicrobial resistance
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Combatting the rise of antimicrobial resistance

Antimicrobial resistance (AMR) is a growing global threat that, without intervention, could lead to as many as 10 million deaths...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

AMR Action Fund invests in new antibiotics developed by BioVersys

The AMR Action Fund has made its first European investment in BioVersys, which is headquartered at Tech Park Basel. The...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Investors give Resistell 8.5 million Swiss francs

Resistell AG has secured 8.5 million Swiss francs in the first part of its series B funding round. The biotechnology...

Read More
1 2 3 60

Do you have a question? We'd like to hear from you.